SNSE
Sensei Biotherapeutics, Inc. NASDAQ Listed Feb 4, 2021$23.30
+30.75%
vs $17.82
Mkt Cap $29.4M
52w Low $6.80
58.4% of range
52w High $35.07
50d MA $21.97
200d MA $16.48
P/E (TTM)
—
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.1x
ROE
-113.4%
P/FCF
-1.4x
RSI (14)
57.60
ATR (14)
$2.96
Beta
-0.10
50d MA
$21.97
200d MA
$16.48
Avg Volume
59.2K
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
451 D Street · Rockville, MD 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -4.81 | -3.74 | +22.2% | 25.13 | -4.9% | +25.4% | +10.4% | -10.8% | +7.6% | -9.6% | — |
| Nov 14, 2025 | AMC | -4.11 | -3.62 | +11.9% | 8.01 | -5.6% | +1.6% | +4.9% | +17.3% | -12.2% | -0.9% | — |
| Aug 5, 2025 | AMC | -6.20 | -3.91 | +36.9% | 8.24 | +0.0% | -5.9% | -7.0% | +6.1% | -2.1% | +0.9% | — |
| May 6, 2025 | AMC | -4.20 | -5.40 | -28.6% | 7.95 | +0.6% | -1.4% | -4.0% | -4.4% | +0.8% | -1.8% | — |
| Mar 28, 2025 | AMC | -5.40 | -5.40 | +0.0% | 10.17 | -15.5% | -22.5% | -12.4% | +6.1% | -11.1% | -11.4% | — |
| Nov 14, 2024 | AMC | -6.20 | -5.80 | +6.5% | 9.24 | -2.3% | -1.8% | +10.7% | -4.4% | +3.8% | -2.8% | — |
| Aug 6, 2024 | AMC | -5.00 | -5.60 | -12.0% | 13.00 | +0.0% | -2.4% | +0.6% | -1.3% | -2.8% | +2.1% | — |
| May 9, 2024 | AMC | -5.80 | -6.40 | -10.3% | 31.40 | +1.9% | -3.8% | +4.0% | -3.8% | -1.3% | +6.7% | — |
| Feb 28, 2024 | AMC | -6.40 | -6.00 | +6.2% | 16.80 | +2.4% | +1.2% | +0.0% | +11.2% | -4.8% | +3.6% | — |
| Nov 7, 2023 | AMC | -5.60 | -5.60 | +0.0% | 14.02 | -7.3% | +10.0% | -6.5% | -0.1% | +4.2% | +0.0% | — |
| Aug 3, 2023 | AMC | -6.40 | -6.20 | +3.1% | 24.00 | -1.3% | +1.7% | +0.0% | +0.0% | +2.5% | -1.6% | — |
| May 9, 2023 | AMC | -7.00 | -6.60 | +5.7% | 30.80 | -3.9% | +0.6% | -3.9% | +0.0% | -2.7% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 | BTIG Research | Initiates | Buy | $55 | $11.41 | $13.27 | +16.3% | -5.4% | +20.5% | +9.1% | +2.5% | +14.6% |
| May 29 | Cantor Fitzgerald | Initiates | Overweight | — | $17.59 | $19.03 | +8.2% | +20.2% | -6.4% | -18.6% | -1.6% | +4.7% |
| May 22 | Citigroup | Initiates | Buy | $55 | $17.56 | $18.47 | +5.2% | +1.3% | -7.4% | +1.1% | +5.6% | +20.2% |
| Oct 30 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $9.38 | $11.40 | +21.5% | +0.9% | -3.1% | -6.1% | +0.8% | +2.2% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.65 | $8.27 | -4.4% | -4.7% | -5.9% | -7.0% | +6.1% | -2.1% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.62 | $10.40 | +20.6% | +18.0% | -22.5% | -12.4% | +6.1% | -11.1% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.62 | $10.40 | +20.6% | +18.0% | -22.5% | -12.4% | +6.1% | -11.1% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.60 | $10.20 | -3.8% | -3.3% | +3.5% | -3.5% | -0.8% | +0.2% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.34 | $10.24 | -1.0% | +2.5% | -3.3% | +3.5% | -3.5% | -0.8% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $13.00 | +0.0% | -2.4% | +0.6% | -1.3% | -2.8% | +2.1% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.00 | $17.80 | -38.6% | -45.5% | +5.1% | +2.3% | -11.1% | -2.1% |
| May 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $29.00 | $17.80 | -38.6% | -45.5% | +5.1% | +2.3% | -11.1% | -2.1% |
| Dec 13 | Citigroup | Maintains | Buy → Buy | — | $34.40 | $35.80 | +4.1% | +1.2% | -9.2% | -1.9% | -5.8% | +4.1% |
| Oct 3 | Oppenheimer | Upgrade | Perform → Outperform | — | $31.00 | $35.00 | +12.9% | +7.1% | +0.6% | -2.4% | +0.0% | -4.9% |
| Mar 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.60 | $64.60 | -1.5% | -7.6% | -10.9% | -2.2% | -8.0% | +7.0% |
| Jul 1 | Berenberg | Downgrade | Buy → Hold | — | $195.20 | $186.40 | -4.5% | -7.0% | -1.1% | -1.7% | -4.5% | -0.7% |
| Jun 29 | Oppenheimer | Downgrade | Outperform → Perform | — | $216.60 | $194.60 | -10.2% | -16.0% | +7.3% | -7.0% | -1.1% | -1.7% |
| Mar 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $330.00 | $346.60 | +5.0% | +3.0% | -5.2% | -2.3% | -7.9% | +3.8% |
| Mar 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $330.00 | $346.60 | +5.0% | +3.0% | -5.2% | -2.3% | -7.9% | +3.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Peyer James | — | Sell | 476 | $21.14 | $10K | 130,142 | -18.65% | -13.31% |
| Jun 1, 2026 | Peyer James | — | Sell | 24,524 | $20.00 | $490K | 130,618 | -18.65% | -13.31% |
| Jun 1, 2026 | Cambrian BioPharma Inc | — | Sell | 476 | $21.14 | $10K | 130,142 | -18.65% | -13.31% |
| Jun 1, 2026 | Cambrian BioPharma Inc | — | Sell | 24,524 | $20.00 | $490K | 130,618 | -18.65% | -13.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,108 | $33.38 | $37K | 133,986 | -2.55% | +1.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 300 | $32.25 | $10K | 133,986 | -2.55% | +1.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 4,423 | $31.38 | $139K | 133,986 | -2.55% | +1.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 205 | $29.71 | $6K | 133,986 | -2.55% | +1.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 2,115 | $28.94 | $61K | 133,986 | -2.55% | +1.31% |
| Apr 7, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 1,108 | $33.38 | $37K | 133,986 | -2.55% | +1.31% |
| Apr 6, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 45 | $31.96 | $1K | 141,029 | -2.55% | +1.31% |
| Apr 6, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,214 | $31.02 | $38K | 141,029 | -2.55% | +1.31% |
| Apr 6, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 1,104 | $31.02 | $34K | 141,029 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,134 | $34.80 | $39K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 374 | $33.35 | $12K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,794 | $32.60 | $58K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,265 | $31.75 | $40K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 3,099 | $30.86 | $96K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 701 | $35.55 | $25K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 1,276 | $34.75 | $44K | 144,974 | -2.55% | +1.31% |
| Apr 2, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 26 | $33.47 | $870 | 144,974 | -2.55% | +1.31% |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 46 | $34.75 | $2K | 147,731 | -2.55% | +1.31% |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,104 | $31.52 | $35K | 147,731 | -2.55% | +1.31% |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 3,401 | $35.46 | $121K | 147,731 | -2.55% | +1.31% |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 1,613 | $34.59 | $56K | 147,731 | -2.55% | +1.31% |
| Apr 1, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Buy | 1,161 | $31.53 | $37K | 147,731 | -2.55% | +1.31% |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 87 | $31.52 | $3K | 146,657 | -2.55% | +1.31% |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 5 | $28.41 | $142 | 146,657 | -2.55% | +1.31% |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 57 | $27.11 | $2K | 146,657 | -2.55% | +1.31% |
| Mar 31, 2026 | MILLENNIUM MANAGEMENT LLC10% | — | Sell | 1,251 | $25.17 | $31K | 146,657 | -2.55% | +1.31% |
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Anand Parikh, former Faeth Therapeutics CEO and co-founder, assumes COO role at Sensei Biotherapeutics, bringing significant biotech leadership experience to strengthen operational management.
Jun 15
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Jun 10
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics filed pro forma financials reflecting potential Series B Preferred Stock conversion, indicating a capital restructuring that could significantly alter shareholder equity and ownership structure.
May 21
8-K · 2.02
!! High
Sensei Biotherapeutics, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K
Unknown — 8-K Filing
SNSE shareholders face a significant corporate restructuring involving conversion and charter amendments, with multiple director resignations that, while reportedly amicable, signal potential strategic shifts requiring shareholder approval.
Apr 16
8-K
Unknown — 8-K Filing
Sensorium Corp (SNSE) acquired Faeth Subsidiary, expanding its asset base and operational scope, which could drive future revenue growth but requires monitoring integration success and debt implications.
Apr 15
8-K
Unknown — 8-K Filing
Sensei's $200 million funding secures runway for key cancer trials while the Faeth acquisition adds a promising oral combination therapy, potentially expanding its pipeline and reducing dilution concerns for existing shareholders.
Mar 30
8-K · 1.01
!!! Very High
Sensei Biotherapeutics, Inc. -- 8-K 1.01: Merger Agreement
Sensei Biotherapeutics agreed to merge with HOLDCO, a transaction that will alter the company's ownership structure and potentially affect shareholder value and stock trading status.
Feb 18
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics appointed a new CFO with significant biotech finance experience, including prior roles at Jaguar Gene Therapy and board positions at Tectonic Therapeutic, strengthening leadership capabilities.
Feb 13
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vivo Capital, Llc | 722,020 | $23M | New | Mar 2026 |
| 2 | Millennium Management | 146,565 | $5M | New | Mar 2026 |
| 3 | Franklin Resources Inc | 133,506 | $4M | New | Mar 2026 |
| 4 | Stempoint Capital Lp | 132,873 | $4M | New | Mar 2026 |
| 5 | Trails Edge Capital Partners, Lp | 125,000 | $4M | New | Mar 2026 |
| 6 | Marshall Wace, Llp | 65,730 | $2M | New | Mar 2026 |
| 7 | Hrt Financial Lp | 58,001 | $2M | New | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 33,025 | $1M | Added | Mar 2026 |
| 9 | Renaissance Technologies Llc | 32,041 | $1M | Added | Mar 2026 |
| 10 | Vanguard Capital Management Llc | 7,750 | $244K | New | Mar 2026 |
| 11 | Ubs Group Ag | 4,529 | $143K | New | Mar 2026 |
| 12 | Citigroup Inc | 294 | $3K | New | Dec 2025 |
| 13 | Jpmorgan Chase & Co | 32 | $804 | — | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 9 | $284 | — | Mar 2026 |
| 15 | Morgan Stanley | 20 | $214 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 6,194 | $189K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 1,416 | $43K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 1,253 | $38K | Feb 2026 |
| 4 | Dimensional US Sustainability Core 1 ETF | 1,173 | $11K | Jan 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 123 | $4K | Feb 2026 |
| 6 | U.S. CORE EQUITY 2 PORTFOLIO | 123 | $1K | Jan 2026 |
| 7 | Guggenheim Active Allocation Fund | 6 | $183 | Feb 2026 |
Valuation
Market Cap
$29.4M
Enterprise Value
$8.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
1.58x
P/S
—
P/FCF
-1.44x
EV/EBITDA
—
Shares Out
1.3M
Financials (TTM)
Revenue
-$4.9M
Net Income
-$184.5M
EBITDA
-$184.3M
Free Cash Flow
-$20.5M
Op Cash Flow
-$20.5M
EPS Basic
$-16.72
EPS Diluted
$-147.90
EPS Forward
$-2.77
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$22.9M
Total Liab.
$4.3M
Total Equity
$18.6M
Cash
$21.2M
LT Debt
$59K
Book Value/Sh
$14.75
Debt/Equity
0.08x
Current Ratio
5.06
Quick Ratio
5.06
Returns & Growth
ROE
-113.4%
ROA
-92.1%
ROIC
-110.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-1293.3%
Price Returns
2W
+6.7%
1M
-20.6%
3M
-30.7%
6M
+151.1%
12M
+250.6%
Technicals
52W High
$35.07
52W Low
$6.80
50d MA
$21.97
200d MA
$16.48
RSI (14)
57.60
ATR (14)
$2.96
Beta
-0.10
Avg Volume
59K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.50
High
$6.00
Low
$5.00
Median
$5.50
Data updated apr 27, 2026 2:14am
· Source: financialmodelingprep.com